17:47:20 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-29 Halvårsrapport
2024-05-16 X-dag ordinarie utdelning BRAINP 0.00 DKK
2024-05-15 Årsstämma
2024-05-07 Bokslutskommuniké 2023
2023-10-11 Extra Bolagsstämma 2023
2023-08-31 Halvårsrapport
2023-05-30 X-dag ordinarie utdelning BRAINP 0.00 DKK
2023-05-26 Årsstämma
2023-04-28 Bokslutskommuniké 2022
2022-09-29 Halvårsrapport
2022-09-02 Extra Bolagsstämma 2022
2022-05-19 X-dag ordinarie utdelning BRAINP 0.00 DKK
2022-05-18 Årsstämma
2022-04-29 Bokslutskommuniké 2021

Beskrivning

LandDanmark
ListaFirst North Denmark
SektorHälsovård
IndustriVård & Omsorg
Brain+ är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom forskning och utveckling för behandling av demens och alzheimers. Produktportföljen inkluderar exempelvis kognitiv stimuleringsterapi. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs med störst närvaro inom Europa. Brain+ har sitt huvudkontor i Köpenhamn.
2023-12-14 18:46:11

Brain+ A/S (Nasdaq First North, Denmark: BRAINP)

This information is information that Brain+ A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on December 14, 2023

Copenhagen, Denmark, December 14, 2023  - Today, Anders Härfstrand has informed the Board of Directors in Brain+ that he has decided to resign as Chairman and member of the board for personal reasons. He will leave the board with effect from 31 January 2024.

Anders Härfstrand was elected as new board member at an Extraordinary General Meeting of the company in September 2022 and has since then held the position as Chairman. With his broad experience and insight into the life science industry and his strong business network, Anders has been a valuable figure in the development of the company over the past 1.5 years.

Kim Baden-Kristensen, CEO and founder of Brain+ commented: "It has been a true pleasure working with Anders. His supportive and direct approach has ensured a constructive and open dialogue and valuable discussions both in the board room and on a day-to-day basis. In full understanding of his decision, I wish Anders all the best going forward."

Brain+ will now start a search for a new board member and chairman to replace Anders.

Contact Information

CEO and Co-founder: Kim Baden-Kristensen, + 45 31393319 (SMS), kim@brain-plus.com
Certified Advisor: Keswick Global AG, + 43 1740408045, info@keswickglobal.com

The mission of Brain+ is to make effective treatments for cognitive decline in Alzheimer's accessible to everyone as digital therapeutics

For further information about Brain+ and CST-Therapist Companion, please visit the company's webpage www.brain-plus.com and LinkedIn profile